Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Corn oil QHC approved

This article was originally published in The Tan Sheet

Executive Summary

Scientific evidence supports a substance/disease relationship linking corn oil consumption to a reduced risk of coronary heart disease, but FDA "believes that the scientific evidence represents a very low level of comfort among qualified scientists that the claimed relationship is scientifically valid," the agency says in a qualified health claim approval March 26. Therefore, enforcement discretion will be exercised for label statements that provide a non-misleading description of the strength of the scientific evidence, such as "very limited and preliminary scientific evidence suggests," FDA notes. The Wood Burditt Group submitted a petition in April 2006 seeking approval of claims such as "substituting corn oil for solid fats may reduce your risk of heart disease." The agency points out in its approval letter that among the intervention studies submitted to support the claim, three did not measure a validated surrogate endpoint of CHD, 17 did not include a control group consuming saturated fatty acids, six did not perform statistical analysis between the intervention and control groups and 17 had a duration of intervention that was too short (less than three weeks)...

You may also be interested in...



Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity

Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.

Topics

UsernamePublicRestriction

Register

PS100353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel